<code id='17D66DBAA3'></code><style id='17D66DBAA3'></style>
    • <acronym id='17D66DBAA3'></acronym>
      <center id='17D66DBAA3'><center id='17D66DBAA3'><tfoot id='17D66DBAA3'></tfoot></center><abbr id='17D66DBAA3'><dir id='17D66DBAA3'><tfoot id='17D66DBAA3'></tfoot><noframes id='17D66DBAA3'>

    • <optgroup id='17D66DBAA3'><strike id='17D66DBAA3'><sup id='17D66DBAA3'></sup></strike><code id='17D66DBAA3'></code></optgroup>
        1. <b id='17D66DBAA3'><label id='17D66DBAA3'><select id='17D66DBAA3'><dt id='17D66DBAA3'><span id='17D66DBAA3'></span></dt></select></label></b><u id='17D66DBAA3'></u>
          <i id='17D66DBAA3'><strike id='17D66DBAA3'><tt id='17D66DBAA3'><pre id='17D66DBAA3'></pre></tt></strike></i>

          Home / comprehensive / hotspot

          hotspot


          hotspot

          author:leisure time    Page View:467
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In